Inauguration of CMA Terminals Khalifa Port Boosts the Port’s Total Container Capacity by 23% to almost 10m TEUs
12.12.2024 18:19:00 CET | Business Wire | Press release
With the new CMA CGM Terminal, Khalifa Port becomes the regional hub headquarters for three of world’s top five shipping companiesCMA Terminals Khalifa Port will play a vital role in enhancing UAE inland and maritime connectivityThe sustainably designed container terminal is operated under a 35-year concession by a joint venture between CMA CGM & AD Ports GroupThe completed phase 1 of CMA Terminals Khalifa Port cost AED 3.1 billion (USD 845 million), and adds 1.8 million TEUs capacity to Khalifa Port
AD Ports Group (ADPORTS:ADX), an enabler of integrated trade, transport and logistics solutions, announced the inauguration of CMA Terminals Khalifa Port, a state-of-the-art, AED 3.1 billion (USD 845 million) container terminal by His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212510462/en/

HH Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Rodolphe Saadè, Captain Mohamed Al Shamisi during the inauguration of CMA Terminals Khalifa Port (Photo: AETOSWire)
The inauguration is a major milestone in the development of Khalifa Port, AD Ports Group’s flagship port. The world-class container, ro-ro, and multipurpose port facility opened in December 2012, and in just 12 years has expanded to become one of the world’s fastest-growing, most efficient commercial ports.
CMA Terminals Khalifa Port, managed by a joint venture between the CMA CGM Group’s subsidiary CMA Terminals (70%) and AD Ports Group (30%), showcases advanced port infrastructure, including automated gates and integrated systems that enhance efficiency and sustainability. The facility offers shore-power for vessels to limit emissions, several solar panels areas contributing to the energy mix of the terminal operations and includes the region’s first net zero carbon administration building, which is powered by renewable energy sources. The building won the Net Zero Building Project of the Year Award in 2022 from the MENA Green Building Awards.
The addition of the CMA CGM facility increases Khalifa Port’s annual container capacity by 23% to almost 10 million TEUs (Twenty Foot Equivalent Units). The new terminal is ready for rail connectivity and will significantly enhance Khalifa Port’s position as a major gateway for the region. The design of the new facility incorporates sustainability principles into the construction which support the UAE’s wider targets for building the circular economy, recycling construction and reducing operational waste.
The new facility includes eight advanced Ship to Shore (STS) cranes, and 20 Electric Rubber Tyred Gantry (e-RTG) cranes, which enhances Khalifa Port’s reputation as one of the world’s most technologically advanced commercial ports, underscoring Abu Dhabi’s role in driving the future of sustainable and smart trade.
H.E. Mohamed Hassan Alsuwaidi, Chairman of AD Ports Group, said: “The inauguration of CMA Terminals Khalifa Port highlights the UAE as a premier investment destination and solidifies its position as a key partner for global players. The new terminal will boost trade flows and foster long-term economic growth in Abu Dhabi and the UAE.”
Rodolphe Saadé, Chairman and Chief Executive Officer of the CMA CGM Group, said: “The inauguration of our new container terminal is a major step in the development of Khalifa Port, consolidating Abu Dhabi's position as a global trade hub. This strategic infrastructure will boost shipping and logistics activities across the region. Together with our partner AD Ports Group, we are pleased to deliver a modern terminal with a strong focus on innovation and sustainability.”
Captain Mohamed Juma Al Shamisi, Managing Director and Group CEO, AD Ports Group, said: “CMA Terminals Khalifa Port will significantly boost Abu Dhabi’s connectivity, reinforcing its vital role on the global trade map and contributing to local economic diversification in line with the vision of our leadership. This new facility places AD Ports Group firmly in the ranks of the world’s leading global port operators. We look forward to a long, mutually beneficial partnership with CMA CGM that brings long-term economic benefits to the UAE and Abu Dhabi, as we work together to build a sustainable global transport future.”
The inauguration of CMA Terminals Khalifa Port marks the completion of Phase 1 of the new terminal project for CMA CGM, with the opening of an initial quay wall of 800 metres 18.5 metres of depth, and 8 STS Cranes adding a total capacity of 1.8 million TEUs (Twenty Foot Equivalent Units) to Khalifa Port.
With the opening of the new CMA CGM facility, Khalifa Port has reached a new stage as one of the region’s leading port trade hubs. Khalifa Port now extends over 6.3 km2, with 41 quay cranes, 159 yard cranes, 11.7 km of quay wall and 3.8 km of breakwater length.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212510462/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom